SUMMARY Two pairs of sibs with definite rheumatoid arthritis responded in a remarkably similar way to parenteral gold therapy, in terms of both toxicity and efficacy. Both pairs proved to be HLA identical. One of the pairs possessed the HLA antigens B8 and DR3, which have been associated with both drug toxicity and excellent clinical response. The other pair did not possess either of these antigens, suggesting that the reaction to gold therapy in patients with rheumatoid arthritis may be determined by other HLA or genetic factors coded for by chromosome 6, or both. 
Parenteral gold is still a cornerstone of drug treatment of rheumatoid arthritis (RA). Disadvantages of the drug are its frequent toxicity and its ineffectiveness in some patients. Recently, associations with certain HLA antigens have indicated that genetic factors have a role in both gold toxicity and effectiveness.'"4 HLA antigens involved include B8 and DR3 in gold toxicity and DR3 in predicting excellent response to the drug.'-3 Another study found a relation between the absence of antigen A3 and the simultaneous presence of antigen DR4 and poor response to parenteral zold. 4 In the present report we describe two pairs of sibs with rheumatoid arthritis who responded in a remarkably similar way to parenteral gold therapy, 
Case reports
All four patients had a symmetrical polyarthritis. Because of a flare, gold was reinstituted one and a half years later. After three months of therapy the disease was in remission, but after a total dose of 800 mg (over nine months) she developed dermatitis again, necessitating stopping the treatment. At that stage there was evidence of onlv slight disease activity.
Discussion
This report shows remarkably similar reactions to parenteral gold therapy in two sib pairs, in terms of both toxicity and favourable clinical response to the drug. Tissue typing showed that the sib pairs were HLA identical. Toxicity on parenteral gold therapy has been found in some studies to be associated with certain HLA antigens, namely HLA-B8 and DR3.2 t7-l These associations were predominantlv found for gold induced proteinuria7x and thrombocytopenia.9 "' Interestingly, an association between the most frequent side effect, i.e., skin rash, and HLA antigens has been found in only a few studies.2 12 Bardin et al found an association with the haplotype Al Cw7 B8 DR3,11 and our group has recently reported an association with HLA-B8 and DR3.t2 It should be stressed, however, that other groups have been unable to find associations between HLA antigens and gold toxicity.13 14 The patients in these two sibships developed the same pattern of toxicity and in addition, showed the same favourable clinical response to the drug. One of the sib pairs possessed the haplotype HLA-B8 and DR3; antigens that have been associated with both gold toxiCityl 2 7-11 and excellent clinical response.3 12 The other sib pair, however, did not possess these antigens. Both patients of the latter sib pair received two courses of gold and on each occasion reacted identically to this treatment. This observation suggests that other genetic factors associated with chromosome 6 may have a role in the reaction to parenteral gold therapy.
Although suggestive, the present data are anecdotal and need to be confirmed by more extensive studies. There is, however, accumulating evidence that genetic factors have a role in the way patients react to antirheumatic drugs, in terms of both side effects and efficacy. 
